Investigator meeting · Dr. Quentin Quinn

06 May 2026 · Virtual · Dr. Quentin Quinn, Institut Curie · MSL Dr. Anna Becker · Nephrada

ReviewedManualENG-0132—

Capture insight from this engagement

Location: Institut Curie
Therapeutic area: Nephrology
Country: France
Stakeholder tier: Tier 1
Strategic objective: Not linked
Initiative: Not linked
MSL: ABDr. Anna BeckerMSL, Nephrology (DACH)
Product: Nephrada (nephradin)

Topics discussed

Treatment burden and fatigue
eGFR slope interpretation
APRIL pathway mechanism

Scientific content used

NPH mechanism-of-action deck
Surrogate-endpoint evidence review

Questions raised

Is there any data on APRIL inhibition in FSGS?
What is the immunoglobulin monitoring recommendation?

Notes

Investigator meeting with academic nephrologist at Institut Curie. Discussed treatment burden and fatigue, egfr slope interpretation, april pathway mechanism.

Insights captured (0)

Capture insight

No insights captured from this engagement.

Review workflow

Draft
Submitted
3Reviewed

Review complete. Quality ratings and insights can now be used in aggregates.

Follow-ups

Send publication reprint

0 of 1 complete

Quality ratings

1–5, rated at review

Scientific relevance: 4
Strategic relevance: 5
Depth of exchange: 5
Actionability: 1

Data lineage

Source system: Manual
Sync: Entered manually in Hub
System of record: Hub
Record id: ENG-0132

Audit history (0)

All create, update and approval events for this record

No audit events in sample data